276 related articles for article (PubMed ID: 9257301)
41. Hemostasis in spontaneous subarachnoid hemorrhage.
Fujii Y; Takeuchi S; Sasaki O; Minakawa T; Koike T; Tanaka R
Neurosurgery; 1995 Aug; 37(2):226-34. PubMed ID: 7477773
[TBL] [Abstract][Full Text] [Related]
42. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients.
Zuo Y; Warnock M; Harbaugh A; Yalavarthi S; Gockman K; Zuo M; Madison JA; Knight JS; Kanthi Y; Lawrence DA
Sci Rep; 2021 Jan; 11(1):1580. PubMed ID: 33452298
[TBL] [Abstract][Full Text] [Related]
43. Levels of catecholamine in plasma and cerebrospinal fluid in aneurysmal subarachnoid hemorrhage.
Dilraj A; Botha JH; Rambiritch V; Miller R; van Dellen JR
Neurosurgery; 1992 Jul; 31(1):42-50; discussion 50-1. PubMed ID: 1641109
[TBL] [Abstract][Full Text] [Related]
44. Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA).
Fodstad H; Nilsson IM
Acta Neurochir (Wien); 1981; 56(1-2):25-38. PubMed ID: 7195642
[TBL] [Abstract][Full Text] [Related]
45. Coagulation and fibrinolytic activity in patients with acute cerebral infarction.
Li F; Zhang G; Zhao W
Chin Med J (Engl); 2003 Mar; 116(3):475-7. PubMed ID: 12781064
[TBL] [Abstract][Full Text] [Related]
46. Changes in coagulation and fibrinolysis and effects of ticlopidine and cisternal drainage in the acute phase following aneurysm rupture.
Toyoda O; Nakajima H; Nukui H
Neurol Med Chir (Tokyo); 1990 Sep; 30(9):670-5. PubMed ID: 1708457
[TBL] [Abstract][Full Text] [Related]
47. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease.
Sutton R; Keohane ME; VanderBerg SR; Gonias SL
Blood Coagul Fibrinolysis; 1994 Apr; 5(2):167-71. PubMed ID: 8054448
[TBL] [Abstract][Full Text] [Related]
48. [Fibrinolytic activity of cerebrospinal fluid in subarachnoid hemorrhage (author's transl)].
Imanaga H; Osugi T; Kagawa M; Kita-Mura K
No Shinkei Geka; 1977 Jan; 5(1):51-8. PubMed ID: 557178
[TBL] [Abstract][Full Text] [Related]
49. Assessment of the haemostatic system in patients surgically treated for ruptured cerebral aneurysm.
Morga R; Czepko R; Dembińska-Kieć A; Danilewicz B
Neurol Neurochir Pol; 2007; 41(4):296-305. PubMed ID: 17874337
[TBL] [Abstract][Full Text] [Related]
50. Cisternal and lumbar CSF levels of arachidonate metabolites after subarachnoid haemorrhage: an assessment of the biochemical hypothesis of vasospasm.
Rodriguez y Baena R; Gaetani P; Silvani V; Viganò T; Crivellari MT; Paoletti P
Acta Neurochir (Wien); 1987; 84(3-4):129-35. PubMed ID: 3107348
[TBL] [Abstract][Full Text] [Related]
51. Haemostasis in cerebrospinal fluid. Basic concept of antifibrinolytic therapy of subarachnoid haemorrhage.
Hindersin P; Heidrich R; Endler S
Acta Neurochir Suppl (Wien); 1984; 34():1-77. PubMed ID: 6395643
[TBL] [Abstract][Full Text] [Related]
52. Early Dynamics of Interleukin-6 in Cerebrospinal Fluid after Aneurysmal Subarachnoid Hemorrhage.
Ďuriš K; Neuman E; Vybíhal V; Juráň V; Gottwaldová J; Kýr M; Vašků A; Smrčka M
J Neurol Surg A Cent Eur Neurosurg; 2018 Mar; 79(2):145-151. PubMed ID: 28869993
[TBL] [Abstract][Full Text] [Related]
53. Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhage.
Findlay JM; Weir BK; Kassell NF; Disney LB; Grace MG
J Neurosurg; 1991 Aug; 75(2):181-8. PubMed ID: 1906533
[TBL] [Abstract][Full Text] [Related]
54. Comparative effects of pulsatile and nonpulsatile flow on plasma fibrinolytic balance in pediatric patients undergoing cardiopulmonary bypass.
Aĝirbaşli MA; Song J; Lei F; Wang S; Kunselman AR; Clark JB; Myers JL; Ündar A
Artif Organs; 2014 Jan; 38(1):28-33. PubMed ID: 24237252
[TBL] [Abstract][Full Text] [Related]
55. Interleukin 12 induces activation of fibrinolysis and coagulation in humans.
Portielje JE; Kruit WH; Eerenberg AJ; Schuler M; Sparreboom A; Lamers CH; Bolhuis RL; Stoter G; Huber C; Hack C
Br J Haematol; 2001 Feb; 112(2):499-505. PubMed ID: 11167854
[TBL] [Abstract][Full Text] [Related]
56. Endothelin and aneurysmal subarachnoid haemorrhage: a study of subarachnoid cisternal cerebrospinal fluid.
Gaetani P; Rodriguez y Baena R; Grignani G; Spanu G; Pacchiarini L; Paoletti P
J Neurol Neurosurg Psychiatry; 1994 Jan; 57(1):66-72. PubMed ID: 8301307
[TBL] [Abstract][Full Text] [Related]
57. Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis.
Opatrný K; Opatrná S; Vít L; Opatrný K
Am J Nephrol; 1998; 18(3):186-92. PubMed ID: 9627033
[TBL] [Abstract][Full Text] [Related]
58. Effect of intrathecal fibrinolytic therapy on clot lysis and vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Ohman J; Servo A; Heiskanen O
J Neurosurg; 1991 Aug; 75(2):197-201. PubMed ID: 1906535
[TBL] [Abstract][Full Text] [Related]
59. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
60. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
